Entyvio (Vedolizumab) Long-Term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab To Other Biologic Agents In Patients With Ulcerative Colitis Or Crohn's Disease
Principal Investigator(s)
Email for information
Funded by
Geneva
Research Start Date
Status
Active
The Overall Study Sponsor has developed a study to assess the safety of vedolizumab versus other biologic agents in the real world setting. The participating physicians will be representative of the gastroenterologists who prescribe vedolizumab, or other biologic agents, per the local prescribing information in the participating countries.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.